Cytoki’s IL-22 program wins support from European syndicate in $45M series A, moves toward clinic for IBD

A project spun out of Novo Nordisk and seeded by Lundbeckfonden has now attracted $45 million in series A funding from a European syndicate to advance a long-acting IL-22 variant into the clinic to treat IBD.

Cytoki Pharma ApS believes its lipidated IL-22 therapeutic could be a best-in-class therapy for inflammatory bowel disease. It plans to test the product in a Phase I/IIa trial due to begin in early 2023, Lundbeckfonden Emerge Managing Partner Christian Elling told BioCentury. Elling is Cytoki’s chairman...